Search review questions

Duration of ICU stay ‐ in total population randomised (in days) · critically ill patients

Death ‐ at 30 days after ICU admission, in total population randomised · critically ill patients

Death ‐ at 180 days after ICU admission, in total population randomised · critically ill patients

Serious adverse events, ‐ in total population randomised ‐ hypoglycaemia · critically ill patients

Occurrence of CIP/CIM ‐ in total population randomised · critically ill patients

Occurrence of CIP/CIM ‐ in screened population · critically ill patients

Presence of PHN 6 months after the onset of the acute herpetic rash2 Clinical diagnostic criteria for PHN in any intensity · people with acute herpes zoster1

Presence of PHN 4 months after the onset of the acute herpetic rash Clinical diagnostic criteria for PHN in any intensity · people with acute herpes zoster1

Adverse events Clinical manifestations · people with acute herpes zoster1

Improved muscle function various methods1 · people with myasthenia gravis

Adverse events · people with myasthenia gravis

Change in impairment 1 to 14 days after the start of treatment ‐ not reported · people with myasthenia gravis

Number of patients with ≥ 50% improvement of pain at 12 weeks or less Duloxetine 60 mg daily 11‐point Likert score · patients with painful neuropathy or chronic pain from diabetic peripheral neuropathy

Adverse events · patients with the chronic pain of fibromyalgia

Number with ≥ 50% pain relief at 12 weeks or less · patients with pain in major depressive disorder

Number with ≥ 30% pain relief at 12 weeks or less · patients with pain in major depressive disorder

Mean improvement in pain at 12 weeks or less Visual analogue scale. Scale from: 0 to 10. · patients with pain in major depressive disorder

Mean improvement in Patient Reported Global Impression of Change at 12 weeks or less · patients with pain in major depressive disorder

Adverse events · patients with pain in major depressive disorder

Mean improvement in pain at 12 weeks or less Duloxetine 60 mg daily 11‐point Likert score Scale from: 0 to 10 · patients with painful neuropathy or chronic pain from diabetic peripheral neuropathy

Number of patients with ≥ 30% improvement in pain at 12 weeks or less Duloxetine 60 mg daily 11‐point Likert scale · patients with painful neuropathy or chronic pain from diabetic peripheral neuropathy

Mean improvement in Patient Reported Global Impression of Change at 12 weeks or less Duloxetine 60 mg daily VAS Scale from: 0 to 10 · patients with painful neuropathy or chronic pain from diabetic peripheral neuropathy

Adverse event leading to cessation All neuropathic pain indications Duloxetine 60 mg daily · patients with painful neuropathy or chronic pain from diabetic peripheral neuropathy

Number with ≥ 50% improvement of pain at 12 weeks or less Duloxetine 60 mg daily 11‐point Likert scale · patients with the chronic pain of fibromyalgia

Number with ≥ 30% improvement of pain at 12 weeks or less Duloxetine 60 mg daily · patients with the chronic pain of fibromyalgia

Mean improvement in the Patient Reported Global Impression of Change at completion of trial Duloxetine 60 mg daily VAS Scale from: 0 to 10 · patients with the chronic pain of fibromyalgia

Mean improvement in pain at 12 weeks or less Duloxetine 120 mg daily LikertScale from: 0 to 10 · patients with the chronic pain of fibromyalgia

Reduction in fatigue of at least 1‐point on the Fatigue Severity Scale between 4 to 12 weeks after commencement of intervention Fatigue Severity Scale (FSS) from 1 to 7 (higher score is worse) · people with fatigue in Guillain‐Barré syndrome

Change in 10 metre timed walk 12 or more weeks after commencement of intervention Time taken to walk 10 metres in seconds · people with fatigue in peripheral neuropathy

Change in speed of completion of 9‐hole peg test (in seconds) · people with fatigue in peripheral neuropathy

Health‐related quality of life 12 or more weeks after commencement of the intervention Change in SF‐36 physical function score SF‐36 Physical Functioning Scale and Physical Component Score · people with fatigue in peripheral neuropathy

Change in participation 12 or more weeks after commencement of intervention (not measured) · people with fatigue in peripheral neuropathy

Health‐related quality of life 12 or more weeks after commencement of the intervention Change in mental function score of SF‐36 SF‐36 Mental Component Score · people with fatigue in peripheral neuropathy

Serious adverse events · people with fatigue in peripheral neuropathy

Change in fatigue 12 or more weeks after commencement of intervention (not measured) · people with fatigue in Guillain‐Barré syndrome

Change in activity limitation 12 or more weeks after commencement of intervention (not measured) · people with fatigue in Guillain‐Barré syndrome

Change in participation 12 or more weeks after commencement of intervention using the Rotterdam Handicap Scale. Scale from: 0 to 36. · people with fatigue in Guillain‐Barré syndrome

Health related quality of life after 12 or more weeks or more after commencement of intervention (not reported) · people with fatigue in Guillain‐Barré syndrome

Serious adverse events · people with fatigue in Guillain‐Barré syndrome

Reduction in fatigue of at least 1 point on the Fatigue Severity Scale (FSS) between 4 to 12 weeks after commencement of intervention (not measured) · people with fatigue in peripheral neuropathy

Change in fatigue 12 or more weeks after commencement of intervention Visual Analogue Scale (VAS) of fatigue · people with fatigue in peripheral neuropathy

Change in activity limitation (ODSS/ONLS) · people with fatigue in peripheral neuropathy

Symptom Severity Scale (Levine) at 3 months or less Participants' self assessment questionnaire. Scale from: 1 to 5. · participants with carpal tunnel syndrome

Minor complications events with minor complications · participants with carpal tunnel syndrome

Functional Status Scale (Levine) at 3 months or less Participants' self assessment questionnaire. Scale from: 1 to 5. · participants with carpal tunnel syndrome

Grip strength at 3 months or less Dynamometer · participants with carpal tunnel syndrome

Overall improvement at more than 3 months Participants' subjective evaluation · participants with carpal tunnel syndrome

Symptom Severity Scale (Levine) at more than 3 months Participants' self assessment questionnaire. Scale from: 1 to 5. · participants with carpal tunnel syndrome

Function Status Scale (Levine) at more than 3 months Participants' self assessment questionnaire. Scale from: 1 to 5. · participants with carpal tunnel syndrome

Grip strength at more than 3 months Dynamometer. Scale from: 0 to 50. · participants with carpal tunnel syndrome